sales volume of Esomeprazole – CRI Report https://www.cri-report.com market research vender! Thu, 02 Dec 2021 07:18:32 +0000 en-US hourly 1 https://www.cri-report.com/wp-content/uploads/2021/01/cropped-shcrilogo-c.jpg sales volume of Esomeprazole – CRI Report https://www.cri-report.com 32 32 Investigation Report on China’s Esomeprazole Market 2021-2025 https://www.cri-report.com/investigation-report-on-chinas-esomeprazole-market-2021-2025/ Thu, 27 May 2021 06:56:10 +0000 https://www.cri-report.com/?post_type=product&p=11654 According to CRI analysis, the sales of Esomeprazole have grown steadily from 2016 to 2019. In 2020, its sales fell by about 6% to CNY1.561 billion in 2020.

The post Investigation Report on China’s Esomeprazole Market 2021-2025 first appeared on CRI Report.

]]> Description
Esomeprazole is a proton pump inhibitor (PPI), which can effectively inhibit gastric acid secretion. It is clinically used to treat gastric acid-related diseases such as gastroesophageal reflux disease (GERD) and erosive reflux esophagitis (ERD). Its product, NEXIUM was developed by AstraZeneca AB. Esomeprazole was approved in China in 2007. By 2020, in addition to AstraZeneca AB, there are more than 10 generic drug manufacturers in the Chinese Esomeprazole market, such as Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Jiangsu Aosaikang Pharmaceutical Co., Ltd. and Chongqing Lummy Pharmaceutical Co., Ltd.

According to CRI analysis, the sales of Esomeprazole have grown steadily from 2016 to 2019. In 2020, its sales fell by about 6% to CNY1.561 billion in 2020. The main reason is that the Covid-19 epidemic has affected the hospital’s overall diagnosis and treatment business, resulting in a decline in its sales. The CAGR of Esomeprazole sales in the Chinese market from 2016 to 2020 is 12%.

CRI predicts that the sales volume of Esomeprazole in the Chinese market will have a restorative growth from 2021 to 2025 with the effective alleviation of the Covid-19 epidemic. In addition, as of the first half of 2021, there are 13 pharmaceutical companies that have applied to enter the Esomeprazole market in China. It can be expected that the price of Esomeprazole will decrease with the addition of new manufacturers, and both sales and sales volume will grow. Moreover, compared with similar drugs, Esomeprazole has the advantages of short-course therapy, stable curative effect, fast and long-lasting effect, so the sales volume of Esomeprazole in China will maintain a growth trend.

Topics Covered:
-The impact of COVID-19 on China’s Esomeprazole market
– Sales value of China’s Esomeprazole 2016-2020
– Competitive landscape of China’s Esomeprazole market
– Prices of Esomeprazole in China
– Prices of Esomeprazole in China by regions and manufacturers
– Analysis of factors affecting the development of China’s Esomeprazole market
– Prospect of China’s Esomeprazole market from 2021 to 2025

The post Investigation Report on China’s Esomeprazole Market 2021-2025 first appeared on CRI Report.

]]>